Article

Animal model vital in future treatment for AMD

Philadelphia, PA-University of Pennsylvania School of Medicine researchers have created the first animal model of age-related macular degeneration (AMD).

Philadelphia, PA-University of Pennsylvania School of Medicine researchers have created the first animal model of age-related macular degeneration (AMD).

"To better develop treatments for preventing the progression of AMD, we need to understand the real biochemical details of how AMD occurs," said lead author Eric A. Pierce, MD, PhD, associate professor of ophthalmology at Penn's K.M. Kirby Center for Molecular Ophthalmology. "To do that, we need a model, and now we have one."

"By making this particular mutant mouse, we've made a model of early macular degeneration that's caused by a mutation we know produces macular degeneration in people," said Pierce. "We think it's going to be a good model to study the pathogenesis of basal deposits."

One type of macular degeneration is thought to be caused by a mutation in the Efemp1 gene. Dr. Pierce and colleagues introduced the disease causing mutation into the Efemp1 gene of the mice.

They plan to use the mice to study how basal deposits form, what they are made of, and to test potential treatments to prevent basal deposit formations. The study is in the October issue of Human Molecular Genetics.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.